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Abstract: We investigated the expression and proinflammatory activity of interleukin 
(IL)-36 in patients with systemic lupus erythematosus (SLE). The expression level of IL-36, 
its putative receptors and the frequency of CD19+CD24highCD27+ regulatory B (Breg) 
lymphocytes of peripheral blood from 43 SLE patients and 16 normal control (NC) subjects 
were studied using ELISA and flow cytometry. Plasma cytokines/chemokines and ex vivo 
productions of cytokine/chemokine from peripheral blood mononuclear cells (PBMC) 
stimulated with recombinant IL-36 were determined by Luminex multiplex assay. Plasma 
concentrations of IL-36α, IL-36γ and the proportions of circulating IL-36R-positive CD19+ 
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B lymphocytes in total B lymphocytes and PBMC were significantly increased in active SLE 
patients compared with NC (all p < 0.05). Plasma IL-36α and IL-36γ correlated positively with 
SLE disease activity and elevated plasma IL-10 concentration (all p < 0.05). The frequencies 
of circulating Breg lymphocytes in total B lymphocytes and PBMC were significantly 
decreased in both inactive and active SLE patients compared with NC (all p < 0.01).  
The frequency of Breg lymphocytes in total B lymphocytes correlated negatively with the 
proportion of IL-36R-positive B lymphocytes (p < 0.05). IL-36α exerted substantial 
proinflammatory effect in PBMC from SLE patients by inducing the production of IL-6 
and CXCL8. Upon stimulation with IL-36α and IL-36γ, ex vivo productions of IL-6 and 
CXCL8 were significantly increased in SLE patients compared with NC (all p < 0.05). This 
cross-sectional study demonstrated that over expression of circulating IL-36α may exert a 
proinflammatory effect as observed in human SLE. 
Keywords: cytokines; IL-36; regulatory B lymphocytes; systemic lupus erythematosus 
 
1. Introduction 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the dysregulated 
activation of both B and T lymphocytes and the subsequent overproduction of auto- antibodies and 
proinflammatory cytokines [1]. It is generally believed that SLE is associated with abnormal cytokine 
levels, including increased T helper cell type 1 (Th1) cytokine [interferon (IFN)-γ], Th2 cytokine 
[interleukin (IL)-4], which stimulate antibodies production, and Th17 cytokines (e.g., IL-17) as well as 
inflammatory IL-1β, IL-6 and IL-18 that may contribute to the pathogenesis of SLE [2–6]. IL-10, primarily 
produced by monocytes, Th2, regulatory T and B lymphocytes, is elevated in SLE patients and correlated 
well with SLE disease activity [7]. These abnormalities indicated a rather complex cytokines network 
which required further investigations in human SLE. 
IL-36 is a newly named cytokine of the IL-1 cytokine family comprising three members,  
IL-36α, IL-36β and IL-36γ (previously designated as IL-1F6, IL-1F8 and IL-1F9, respectively) [8,9]. 
All three IL-36 isoforms bind to a heterodimer consisting of IL-36 receptor (IL-36R, previously called 
IL-1Rrp2/IL-1R6) and IL-1RAcP, a common co-receptor, which together activate intracellular signals 
similar to those induced by IL-1. IL-36R antagonist (IL-36Ra) binds to IL-36R without inducing any 
signaling response, thereby acting as a natural inhibitor similar to IL-1Ra/IL-1 system [10]. At present, it 
is believed that IL-36 expressed in a few human tissues in a restricted manner, primary by keratinocytes 
in the skin and other epithelial cell types upon exposure to pathogens [11]. Evidences based on the 
expression pattern of IL-36 and its receptor in human psoriasis and mouse models have defined a crucial 
pathological role for IL-36 in skin inflammation, partly by acting on the crosstalk between keratinocytes 
and inflammatory dendritic cells (DC) [12,13]. The relationship between Th17 cytokines and IL-36 
has also been previously established in human keratinocyte culture [14]. IL-36 expression can be 
up-regulated by Th17 cytokines and in turn, IL-36 production can regulate the expression and enhance 
the function of Th17 cytokines in an autocrine manner [14]. Notably, Vigne et al. found that IL-36 can 
skew the differentiation of naive mouse T cells into IFN-γ-producing Th1 cells [15]. Moreover, they 
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demonstrated that IL-36 can promote the maturation of DC and stimulate mouse bone-marrow-derived 
DC to produce inflammatory cytokines at a higher level than other IL-1 family members, highlighting 
its potential role in bridging the innate and adaptive immunity [16].  
Regulatory B (Breg) lymphocytes have an important role in suppressing auto-reactive and 
pathogen-driven immune response by secreting anti-inflammatory cytokine IL-10 [17]. Dysregulation 
of Breg lymphocytes may be involved in the development of various autoimmune diseases including  
SLE [18]. In humans, different B cell subsets are enriched in Breg cells, mainly including CD24highCD27+ 
and CD24highCD38high B cell subsets. Previous studies have reported the lack of suppressive capacity 
regarding CD19+CD24highCD38high Breg lymphocytes in SLE patients and CD19+CD24highCD27+  
Breg lymphocytes in Graves’s disease and graft-versus-host disease [19–21]. However, the role of 
CD19+CD24highCD27+ Breg lymphocytes and the novel proinflammatory cytokine IL-36 in the 
regulation of human SLE remains unknown. In this context, we investigated the expression pattern and 
function of IL-36 and IL-36R in peripheral blood of SLE patients, in an attempt to elucidate the 
immunological roles of IL-36 and CD19+CD24highCD27+ Breg lymphocytes and their contribution in 
the cytokine network of SLE. 
2. Results and Discussion 
2.1. Demographical and Clinical Characteristics of SLE Patients and NC 
Forty-three Chinese SLE patients were recruited and divided into two groups according to  
disease activity. Sixteen age- and sex-matched healthy Chinese volunteers were recruited as controls. 
Demographics and clinical characteristics are summarized in Table 1. Plasma albumin concentration 
was significant lower in inactive and active SLE patients (38 ± 7 g/L, and 31 ± 5 g/L, respectively) 
compared with NC (45 ± 2 g/L, both p < 0.01). Similarly, patients with inactive and active SLE had 
lower plasma total protein concentration compared with NC (both p < 0.01). Clinical manifestations at 
the time of study included nephritis (34/43, 79.1%), serositis (12/43, 27.9%), hematologic derangement 
(11/43, 25.6%) and arthritis (17/43, 39.5%) of all the studied SLE patients.  
Table 1. Demographic and clinical characteristics of SLE patients and NC. 
 
SLE Patients (n = 43) Normal Control 
(n = 16) Inactive SLE (n = 22) Active SLE (n = 21) 
Demographic Characteristics 
Female sex (n) (%) 20 (90.9) 13 (95.2) 14 (87.5) 
Age at study (year) 
Mean(SD) 45.2 (9.5) 48.2 (10.5) 41.4 (12.5) 
Range 24–59 23–60 23–57 
Clinical Features 
SLE duration (year) 
Mean(SD) 14.8 (5.9) 16.6 (7.6) N/A 
Range 1–28 10–26 N/A 
SLICC median(IQR) 0 (0–1) 0 (0–3) N/A 
SLEDAI median(IQR) 2 (2–4) 8 (6–16) N/A 
Flare (n) (%) 5 (22.7) 16 (76.2) N/A 
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Table 1. Cont. 
 
SLE Patients (n = 43) Normal Control 
(n = 16) Inactive SLE (n = 22) Active SLE (n = 21) 
Serological Features    
Serum complement C3 (g/L) mean (SD) 0.80 (0.24) 0.62 (0.19) N/A 
Serum complement C4 (g/L) mean (SD) 0.15 (0.09) 0.08 (0.05) N/A 
Anti-dsDNA >1000 IU/mL (n) (%) 2 (9.1) 3 (14.2) N/A 
Anti-dsDNA <60 IU/mL (n) (%) 3 (13.6) 1 (4.8) N/A 
Anti-dsDNA titer (IU/mL) mean (SD) 268.4 (185.1) 409.6 (201.7) N/A 
Plasma urea (mmol/L) mean (SD) 5.8 (1.7) * 6.3 (1.5) ** 4.7 (1.2) 
Plasma creatinine (μmol/L) mean (SD) 70.2 (28.0) 79.5 (30.3) * 61.7 (12.9) 
Plasma total protein (g/L) mean (SD) 70.3 (10.9) ** 66.1 (8.7) *** 77.6 (3.3) 
Plasma albumin (g/L) mean (SD) 38.2 (7.2) ** 31.9 (5.2) *** 45.6 (2.3) 
Major Organ System Involvement (n) (%) 
0 5 (22.7) 0 (0) N/A 
1 10 (45.4) 7 (33.3) N/A 
≥2 7 (32.9) 14 (66.7) N/A 
Clinical Manifestation (n) (%) 
Nephritis 13 (59.1) 21 (100.0) N/A 
Serositis 5 (22.7) 7 (33.3) N/A 
Hematologic 5 (22.7) 6 (28.6) N/A 
Arthritis 8 (38.1) 9 (42.8) N/A 
Current Immunosuppressive Therapy 
Treatment with prednisolone 
Patients (n) (%) 17 (77.3) 19 (90.5) N/A 
Daily dose (mg) mean (SD) 7.5 (3.5) 9.2 (5.7) N/A 
Treatment with hydroxychloroquine 
Patients (n) (%) 9 (40.9) 10 (47.6) N/A 
Daily dose (mg) mean (SD) 236.7 (95.1) 300.0 (115.5) N/A 
Treatment with mycophenolatemofetil    
Patients (n) (%) 10 (45.4) 10 (47.6) N/A 
Daily dose (mg) mean (SD) 883.3 (458.1) 1000.0 (250.0) N/A 
Treatment with lisinopril 
Patients (n) (%) 11 (50.0) 13 (61.9) N/A 
Daily dose (mg) mean (SD) 9.6 (7.4) 14.4 (5.3) N/A 
Treatment with azathioprine 
Patients (n) (%) 4 (18.2.7) 7 (33.3) N/A 
Daily dose (mg) mean(SD) 58.3 (38.2) 100.0 (50.0) N/A 
SD, standard deviation; N/A, not applicable; Inactive SLE: SLEDAI < 6, Active SLE: SLEDAI ≥ 6; SLEDAI, 
systemic lupus erythematosus disease activity index; SLICC, Systemic Lupus International Collaborating 
Clinics Score; Major organ system involvement includes: musculoskeletal, kidney, skin, heart and hematologic 
(hemolytic anemia, platelet < 100,000/μL); ‘‘Flare’’ is defined as increase in the SLEDAI score by 3 or 
more. * p < 0.05, ** p < 0.01 and *** p < 0.001 when compared with normal control. 
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2.2. Elevated Plasma IL-36 Correlated Positively with SLE Disease Activity and Plasma IL-10 
Given the proinflammatory nature of IL-36 in psoriasis, the identification of these new members 
raised intriguing possibilities that IL-36 might also be involved in SLE. We examined the plasma 
concentrations of these novel cytokines and their receptor by ELISA in inactive (n = 22), active (n = 21) 
SLE patients and NC subjects (n = 16). There were detectable IL-36α, IL-36γ and IL-36R present in the 
plasma of both NC and SLE patients. As shown in Figure 1, a comparable plasma IL-36R concentration 
was displayed by all SLE patients, whereas the levels of IL-36α and IL-36γ were significantly higher 
in active SLE patients than those in NC (3.6 ± 0.2 vs. 2.0 ± 0.2 ng/mL and 1.2 ± 0.1 vs. 0.7 ± 0.1 ng/mL, 
respectively, both p < 0.05). We also found higher concentrations of plasma IL-10, IFN-γ, IL-17A and 
CCL2 in SLE patients compared with NC (all p < 0.05, Figure 2). 
 
Figure 1. Comparison of plasma IL-36 concentrations between SLE patients and NC. 
Plasma concentrations of (A) IL-36α; (B) IL-36γ and (C) IL-36R from inactive (n = 22) 
and active (n = 21) SLE patients and NC (n = 16) were measured using ELISA. Results are 
presented as scatter plots with median. Statistical significances were indicated by * p < 0.05 
(Mann-Whitney U test). 
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Figure 2. Comparison of plasma cytokines/chemokines concentrations between SLE patients 
and NC. Plasma concentrations of (A) IL-10; (B) IFN-γ; (C) IL-17A and (D) CCL2 from 
inactive (n = 22) and active (n = 21) SLE patients and NC (n = 16) were measured using 
Milliplex MAP assay kit. Results are presented as box and whisker plots with median 
(interquartile range). Statistical significances were indicated by * p < 0.05, ** p < 0.01 and 
*** p < 0.001 (Mann-Whitney U test). 
Since SLE is associated with low serum concentrations of complements C3 and C4, we further 
investigated the correlations of plasma IL-36 with SLEDAI score, serum complements C3 and C4 as 
well as several common cytokines/chemokines in all the studied SLE patients (n = 43). As illustrated 
in Table 2, IL-36α and IL-36γ correlated positively with SLEDAI score (r = 0.382 and r = 0.327, 
respectively, both p < 0.05). IL-36γ, but not IL-36α, correlated negatively with serum C4 (r = −0.339,  
p < 0.05). We further found that plasma IL-36α and IL-36γ concentrations correlated positively with 
the elevated IL-10 concentrations (r = 0.306 and r = 0.338, respectively, both p < 0.05). No obvious 
correlations of IL-36 with other common cytokines/chemokines (IFN-γ, IL-17A and CCL2) were found 
in all the SLE patients (p > 0.05, data not shown). 
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Table 2. Correlations of plasma IL-36 concentrations with SLE disease activity and IL-10. 
 
IL-36α (ng/mL) IL-36γ (ng/mL) 
r Value p Value r Value p Value 
SLEDAI 0.382 0.011 * 0.327 0.025 * 
C3 (g/L) −0.147 0.342 −0.211 0.154 
C4 (g/L) −0.138 0.371 −0.339 0.019 * 
IL-10 (pg/mL) 0.306 0.046 * 0.338 0.023 * 
N = 43; Non-parametric Spearman’s test was used to assess the correlations. r = Spearman’s correlation 
coefficient. * p < 0.05 
2.3. Elevated Proportion of CD19+ B Cells Expressed with IL-36R in SLE Patients 
IL-36 cytokines mediate signal through IL-36R and the recruitment of the co-receptor IL-1RAcP [10]. 
Flow cytometric analysis showed that IL-36R was strongly expressed on the surface of CD138+ plasma 
cells (Figure 3C) and certain population of CD19+ B lymphocytes (Figure 3A), while its expression was 
absent on the cell surface of CD4+ Th lymphocytes (Figure 3B). Alternatively, IL-1RAcp was expressed 
on the surface of CD19+ B lymphocytes (Figure 3D), CD4+ Th lymphocytes (Figure 3E) and CD138+ 
plasma cells (Figure 3F). Firstly, we examined the proportion IL-36R+ B cells within CD19+ B cells 
gating. The representative dot plots of IL-36R+ B lymphocytes are shown in Supplementary Figure S1. By 
comparing with NC (n = 13), higher IL-36R+ B cells % in total B cells (29.9% ± 1.3% vs 23.9% ± 1.7%, 
p < 0.05) was observed in active SLE patients (n = 14), but not inactive SLE patients (n = 18, Figure 3G). 
Similarly, higher IL-36R+ B cells % among the total number of PBMC were presented comparing with 
NC (1.3% ± 0.3% vs. 0.5% ± 0.1%, p < 0.05, Figure 3H). As shown in Figure 3I, the expression level 
of IL-1RAcP on the surface of CD4+ Th lymphocytes was significantly upregulated in both active (n = 21) 
and inactive (n = 22) SLE patients (1.7% ± 0.1% and 1.7% ± 0.1% vs. 1.1% ± 0.2%, respectively, both 
p < 0.05) compared with NC (n=16). 
 
Figure 3. Cont. 
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Figure 3. Expression profile of IL-36 receptors on the surface of immune cells. (A–C) 
Representative histograms of IL-36R expression on CD19+ B cells, CD4+ Th cells and CD138+ 
plasma cells in SLE patients and NC; (D–F) Representative histograms of IL-1RAcp 
expression on CD19+ B cells, CD4+ Th cells and CD138+ plasma cells in SLE patients  
and NC; (G–I) The proportion of IL-36R+ B cells in total B cells and PBMC from inactive  
(n = 18), active (n = 14) SLE patients and NC (n = 13), and the expression level of 
IL-1RAcP on CD4+ Th cells from inactive (n = 22), active (n = 21) SLE patients and NC  
(n = 16) were detected using flow cytometry. Results are presented as scatter plots with 
median of the proportion or mean fluorescence intensity (MFI) subtracting corresponding 
isotypic controls. Statistical significance indicated by * p < 0.05 when compared with NC 
(Mann-Whitney U test). 
There was no significant difference of IL-1RAcp expression level on CD19+ B cells and CD138+ 
plasma cells of SLE patients comparing with controls, and similar expression level of IL-36R on CD138+ 
plasma cells was found between SLE patients and NC (all p > 0.05, Supplementary Figure S2). 
2.4. Decrement of CD19+CD24highCD27+ Breg Lymphocytes in SLE Patients  
Human circulating Breg lymphocytes are defined as CD19+ B cells with surface expression of CD24 
and CD27. Given the potential contribution of Breg in autoimmunity [18], we evaluated the frequency of 
Breg cells in SLE patients. In NC (n = 16), Breg lymphocytes composed 23.8% ± 3.3% of B lymphocytes 
and 0.6% ± 0.1% of PBMC, while in inactive (n = 22) and active (n = 21) SLE patients, corresponding 
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proportions were 13.1% ± 2.1% and 9.5% ± 1.7% of B lymphocytes, respectively, and 0.3% ± 0.1% 
and 0.2% ± 0.1% of PBMC, respectively. The frequencies of circulating CD19+CD24highCD27+ Breg 
lymphocytes of total B cells and of PBMC were significantly decreased in active and inactive SLE 
patients compared with NC (Figure 4A–C, all p < 0.01). 
 
 
 
Figure 4. Comparison of circulating CD19+CD24highCD27+ Breg lymphocytes frequency 
between SLE patients and NC. (A) Representative dot plots are shown for the 
CD19+CD24highCD27+ Breg lymphocytes gated from CD19+ B cells in SLE patients and 
NC; (B,C) The proportion of circulating Breg lymphocytes from inactive (n = 22) and active 
(n = 21) SLE patients and NC (n = 16) in total B cells and in PBMC were determined by 
flow cytometry. Results are presented as scatter plots with median. (D) Correlation 
between % CD19+IL-36R+ B cells and % CD19+CD24highCD27+ Breg cells was analyzed 
with Spearman’s test. Statistical significances are indicated by ** p < 0.01 and *** p < 0.001 
when compared with NC (Mann-Whitney U test). 
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Furthermore, we were interested in studying the correlations among the frequency of circulating 
Breg lymphocytes and the proportion of IL-36R+ B cells in all the studied patients. As shown in Figure 4D, 
the frequency of CD19+CD24highCD27+ Breg cells in total B cells correlated negatively with the 
proportion of IL-36R+CD19+ B cells (r = −0.424, p = 0.016; n = 32) in SLE patients. 
2.5. IL-36 Promotes the Production of Cytokine/Chemokine in PBMC 
The above findings prompted us to investigate the ability of IL-36 to induce proinflammatory and/or 
anti-inflammatory cytokines and chemokines involved in immune and inflammatory responses. We did 
not observe any significant difference of ex vivo production of cytokine/chemokine between inactive 
and active SLE patient groups, however, PBMC from both SLE patients and NC could be activated by 
human recombinant IL-36α or IL-36γ (both at 1 μg/mL, Table 3). In SLE patients, compared with 
unstimulated control, IL-36α induced markedly higher production of inflammatory IL-6 and CXCL8 
(p < 0.05 and p < 0.01, respectively). In addition, compared with NC, PBMC from SLE patients 
constitutively produced higher level of IL-6 and CXCL8 (both p < 0.01). Upon stimulation with IL-36α 
and IL-36γ, IL-6 and CXCL8 showed significantly higher concentrations in the culture supernatant of 
PBMC from SLE patients (all p < 0.05). Notably, IL-36α and IL-36γ failed to upregulate the production 
of Th1 cytokine IFN-γ in the PBMC culture of both NC and SLE patients (data not shown). Moreover, 
the production of IL-17 was barely detectable in all the treated or untreated control groups. 
Table 3. Ex vivo induction of cytokine/chemokine from PBMC stimulated with IL-36. 
Cytokine/ 
Chemokine 
Group 
Basal  
Median (IQR) (pg/mL) 
Post stimulation with IL-36α 
Median (IQR) (pg/mL) 
Post stimulation with IL-36γ 
Median (IQR) (pg/mL) 
IL-6 
NC 2.3 (0–3.9) 5.6 (1.9–10.4) # 3.6 (1.5–6.6) 
SLE 26.5 (3.6–43.4) *** 44.4 (9.9–90.96) ***,& 35.1 (7.3–65.4) *** 
CXCL8 
NC 548.3 (399.1–676.1) 1347.0 (785.6–2586.0) ### 808.6 (505.2–1300.0) # 
SLE 1288.0 (1145.0–4487.0) ** 2661.0 (1145.0–4487.0) *,&& 1510.0 (678.1–3673) * 
IFN-γ NC 11.9 (10.4–19.4) 16.1 (11.9–27.2) 14.3 (6.6–23.6) 
SLE 14.5 (9.3–20.2) 17.4 (11.3–21.6) 17.4 (11.9–23.0) 
IL-17A 
NC UD UD UD 
SLE UD UD UD 
The culture supernatant was derived from PBMC cultured with medium in the presence of human recombinant 
IL-36α and IL-36γ (1 μg/mL) for 24 h. * p < 0.05, ** p < 0.01 and *** p < 0.001 when compared with NC;  
# p < 0.05 and ### p < 0.001 when compared with untreated control in NC group; & p < 0.05 and && p < 0.01 
when compared with untreated control in SLE group. UD: undetectable. 
Our present study has examined the detailed expression pattern of IL-36 and its receptor, as well as 
the functional consequences of IL-36R signaling way in SLE patients. We have demonstrated higher 
plasma concentrations of IL-36α and IL-36γ in active SLE patients compared with NC (Figure 1). 
Furthermore, the elevated IL-36α and IL-36γ correlated positively with SLEDAI and the elevated plasma 
IL-10, while IL-36γ correlated negatively with serum complement C4 (Table 2), suggesting that plasma 
IL-36 values may reflect SLE disease activity. After statistical analysis, we observed that there were no 
significant effects of drug treatment on IL-36 expression in SLE patients (all p > 0.05). Prompted by the 
high expression of plasma IL-36α and IL-36γ in SLE patients, we investigated the activity of IL-36R 
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on immune cells in peripheral blood of SLE patients. It has been reported that mouse CD4+, but not 
CD8+ T cells, respond to IL-36 in an IL-36R-dependent manner and IL-36 synergizing with IL-12 can 
drive a potent murine Th1 differentiation [15]. However, in contrast to mouse, we found that human CD4+ 
Th cells do not express IL-36R (Figure 3B), which is consistent with a previous study [22]. Importantly, 
about 30% B cells displayed surface expression of IL-36R in peripheral blood of SLE patients. The 
proportion of IL-36R+ B cells of total B cells and PBMC showed a small but significant elevation  
in SLE patients compared with NC (Figure 3G–H). Collectively, the increased levels of IL-36 and 
IL-36R may imply a potential role of IL-36/IL-36R signaling system in the inflammatory pathogenesis 
of chronic autoimmune disease SLE. 
IL-36/IL-36R signaling complex has been previously proved to exert proinflammatory effects 
contributing to the pathogenesis of skin inflammation [23,24]. In addition, overexpressed of circulating and 
tissue levels of IL-36α were also reported in autoimmune disease primary Sjögren’s syndrome [25]. 
Some studies have shown that IL-36 does not participate in the inflammatory progression of experimental 
arthritis though up-regulated IL-36α was found in the synovial tissue of patients with rheumatoid 
arthritis [26–28]. Our present result of non-significant difference of plasma IL-36 concentrations between 
inactive SLE patients (SLEDAI < 6) and normal controls (Figure 1A) was actually in concordance 
with previous publication of Zhang et al. [29] using SLE patients with SLEDAI < 6. Nevertheless, we 
have demonstrated a significant higher plasma IL-36α and IL-36γ concentrations in active SLE patients 
(SLEDAI ≥ 6) compared with NC (Figure 1A,B). Moreover, in all the studied SLE patients, these 
cytokines were found to be correlated positively with disease severity and plasma IL-10, which is 
considered to be a biomarker in human SLE [7], providing evidence that IL-36 might be involved in 
the pathogenesis of human SLE, especially during the late-stage of the disease. Although skin is often 
affected by SLE, there was no significant difference of plasma IL-36 concentrations among SLE 
patients with or without malar rash and normal controls in this study (all p > 0.05). 
Emerging evidence has suggested that Breg subset could down-modulate adaptive or innate 
immune responses in mice and humans. Our present study, for the first time, characterized the 
CD19+CD24highCD27+ Breg subset in patients with SLE. We found that the frequencies of Breg 
lymphocytes were significantly decreased in both inactive and active SLE patients compared with NC 
(Figure 4). Furthermore, correlation study revealed that the frequency of CD19+CD24highCD27+ Breg 
lymphocytes correlated negatively with the proportion of IL-36R+ B cells (Figure 4D). Although we 
did not find a significant correlation of plasma IL-36 concentrations with Breg cell subpopulation  
(p > 0.05), the decreased CD19+CD24highCD27+ Breg lymphocytes in SLE patients imply its important 
contribution in regulating immune response and there may be a reverse inter-regulation between 
circulating inflammatory IL-36 and anti-inflammatory Breg subpopulations. We found IL-36R expressed 
on certain proportion of B cells (Figure 3A and Supplementary Figure S1), but we could not identify 
which B cell subset expressing IL-36R using B cell markers (IgD, CD38, CD24 and CD27) with PBMC 
purified from human buffy coat of normal blood donor (data not shown). However, the evaluation of 
IL-36R+ B cell subset such as Breg and how IL-36 modulates IL-10-producing-Breg lymphocytes in 
SLE patients is required for further investigation.  
Our functional experiments revealed that IL-36α and IL-36γ, both of which are known to exhibit the 
same biological activities [11], have functional consequences in SLE patients. IL-36α and IL-36γ can 
stimulate PBMC to produce proinflammatory IL-6 and CXCL8 in NC and/or SLE patients (Table 3). 
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Such direct stimulatory effects of IL-36 have also been reported on human keratinocyte, mouse splenocytes, 
bone marrow-derived DC and CD4+ Th cells [16,30]. Furthermore, the ex vivo productions of IL-6 and 
CXCL8 from PBMC of SLE patients were markedly higher which may lead to a more complex cytokine 
inter-regulation network for the pathogenesis of human SLE. It further supported the correlation 
between IL-36 and SLEDAI. Previous study showed that IL-36 could skew differentiation of naive 
mouse T cells toward IFN-γ-producing Th1 cells [15]. In contrary, we observed no enhanced expression 
of Th1-producing cytokine, IFN-γ, in PBMC culture supernatant upon the exposure to IL-36α and 
IL-36γ. Moreover, plasma IL-36 seemed not to be related with plasma IFN-γ. This discrepancy could 
possibly due to the absence of IL-36R on human CD4+ Th cells, as demonstrated in Figure 3B and 
another study [22]. Thus, IL-36 may not participate in Th1 subset differentiation in human. Although 
we did not observe a direct effect of IL-36 on IL-17 production and a relationship between plasma IL-17 
and IL-36, we demonstrated a significant increase of circulating CD3+IL-22+IL-17+ T lymphocytes in 
SLE patients in the present study (Supplementary Figure S3). Further investigation to clarify how IL-36 
modulates Th17 cells responses in SLE patients using larger patients sample size would be of interest. 
Despite the effect of the use of high recombinant IL-36 concentrations is still unknown, we found that 
PBMC cultured under optimized conditions after concentration gradient experiment (Supplementary 
Figure S4) to have intact cell viability for the entire culture period. Interestingly, Magne et al. reported 
that endogenously produced IL-36β is active at much lower doses than recombinant IL-36β [31]. This 
prompted us to consider the possibility that human IL-36 cytokines may exert its full biological activities 
via posttranslational modification under physiological conditions [32]. Therefore, such phenomenon 
might be absent or inefficient in the current ex vivo culture by the sole exogenous use of the commercial 
recombinant human IL-36.  
3. Experimental Section 
3.1. Ethics Statement 
Ethics approval for this study was obtained from Clinical Research Ethics Committee of The Chinese 
University of Hong Kong-New Territories East Cluster Hospitals (reference number: CRE2013.451). 
All participants provided written and informed consent in accordance with the 1964 Declaration of 
Helsinki and its later amendments. 
3.2. SLE Patients and Normal Control (NC) Subjects 
Forty-three Chinese patients with SLE were recruited in the rheumatology clinic of the Prince of 
Wales Hospital for this cross-sectional study. All patients fulfilled the revised American College of 
Rheumatology (ACR) criteria for SLE [33]. Patients were excluded from the study if they had prior 
treatment with therapeutic monoclonal antibody or other biologic agents. Patients were divided into 
two groups according to their disease activity as reflected by SLE disease activity index (SLEDAI). 
Group 1: patients with inactive disease activity (SLEDAI < 6, n = 22) and Group 2: patients with active 
disease activity (6 ≤ SLEDAI < 24, n = 21). Sixteen age- and sex- matched Chinese normal control 
subjects were also recruited (NC, n = 16). 
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3.3. Clinical and Laboratory Parameters  
Patient information on demographic characteristics, clinical features, serological profile and medications 
were retrieved from medical records. Laboratory investigations including complete blood count, renal 
and liver function test, and measurement of anti-double stranded DNA (dsDNA) antibody titer, and 
serum complements C3 and C4 concentrations were performed at study visit. Serum anti-dsDNA titer 
was measured by ELISA (Euroimmun, Luebeck, Germany). Complements C3 and C4 were assayed 
using immunonephelometry (Cobas 8000 modular analyzer, Roche Diagnostics Corp., Indianapolis, 
IN, USA). Major organ system involvement was defined as the involvement of one or more of the 
following organs including the musculoskeletal, kidney, skin, heart and hematologic system (hemolytic 
anemia, platelet < 100,000/μL). The prescription of immune- suppressive agents including prednisolone, 
hydroxychloroquine (HCQ) and mycophenolate mofetil (MMF) was recorded from case notes. 
3.4. Assays for the Expression Level of Plasma IL-36α, IL-36γ and IL-36R 
Plasma concentrations of IL-36α/IL-1F6, IL-36γ/IL-1F9 and IL-36R/IL-1R6 of SLE patients and NC 
were measured by enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer’s 
instructions (RayBiotech Inc., Norcross, GA, USA). The intra- and inter-assay coefficient of variability 
(CV) of each kit is below 10% and 12%, respectively. The sensitivity of IL-36α, IL-36γ and IL-36R 
ELISA kit is 800, 13 and 24 pg/mL, respectively. Plasma from SLE patients and NC subjects were 
harvested and stored at −80 °C and all plasma samples were measured on the same ELISA plate.  
3.5. Assays for the Expression Level of Plasma Cytokines/Chemokines 
Plasma from SLE patients and NC subjects were harvested and stored at −80 °C for subsequent 
Multiplex Immunoassay of cytokines and chemokines using Luminex multiplex assay kit from Merck 
Millipore, Corp. (Billerica, MA, USA). 
3.6. Flow Cytometry  
For the analysis of IL-36 receptors expression, peripheral blood mononuclear cells (PBMC) from SLE 
patients and NC were purified using Ficoll Plus gradient centrifugation (GE Healthcare Bio-Sciences, 
Piscataway, NJ, USA) from EDTA venous peripheral blood (20 mL). Indirect immunofluorescent 
staining was used by incubating PBMC with goat anti-human IL-36R, IL-1RAcp, and normal goat  
IgG control antibodies (Ab, R & D Systems, Minneapolis, MN, USA) at 4 °C for 30 min in the dark. 
Then cells were washed and incubated with PE-conjugated donkey anti-goat IgG (R & D Systems), 
FITC-conjugated anti-human CD4 (clone L200), PerCP-conjugated anti-human CD19 Ab (clone 
SJ25C1) and APC-conjugated anti-human CD138 Ab (clone MI15, BD Pharmingen Corp., San Diego, 
CA, USA) at 4 °C for 30 min in the dark. After washing, the expression of cell surface molecules was 
analyzed by Navios flow cytometry (Beckman Coulter, Brea, CA, USA) and the results were expressed 
as the percentage or mean fluorescence intensity (MFI).  
To determine the frequency of circulating CD19+CD24highCD27+ Breg lymphocytes, PBMC were 
purified before surface staining with FITC-conjugated anti-human CD24 (clone ML5), APC-conjugated 
anti-human CD27 (clone M-T271), PerCP-conjugated anti-human CD19 Ab (clone SJ25C1) and their 
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corresponding isotype control Ab (BD Pharmingen Corp.) at 4 °C for 45 min in the dark. After 
washing, the proportion of CD19+CD24highCD27+ Breg lymphocytes was quantified by Navios flow 
cytometer (Beckman Coulter). 
3.7. Ex vivo Induction of Cytokine/Chemokine from PBMC by Recombinant IL-36 
Aliquots of suspended PBMC (1 × 105 cells) in culture medium RPMI1640 supplemented with 10% 
fetal calf serum (Life Technologies, Grand Island, NY, USA) were dispensed in each well of a 96-well 
plate (Nalge Nunc International, Naperville, IL, USA). The culture medium used was free of detectable 
endotoxin (<0.1 EU/mL). The cells were then incubated with or without human recombinant IL-36α and 
IL-36γ (R & D Systems) at 1 μg /mL for 24 h at 37 °C in a 5% CO2 atmosphere. The cell-free supernatant 
was harvested and stored at −80°C for subsequent Milliplex MAP kit assay reagent (Merck Millipore) 
with the Bio-Plex 200 suspension array system (Bio-Rad Laboratories, Hercules, CA, USA) of cytokines 
and chemokines. 
3.8. Statistical Analysis 
Results were expressed as mean ± standard deviation (SD), or median (interquartile range, IQR)  
if data were not normally distributed. All statistical analysis was performed by the SPSS statistical 
software for Windows, version 10.1.4 (SPSS, Chicago, IL, USA). For continuous variables, statistical 
significance was calculated using Mann-Whitney U test. Non-parametric spearman’s test was used to 
assess the correlation of two variables. All hypotheses were 2-tailed, and p values < 0.05 were considered 
to be significant. 
4. Conclusions 
Taken together, our current cross-sectional patient study demonstrated plasma concentrations of novel 
proinflammatory cytokine IL-36α, IL-36γ and peripheral IL-36R+ B lymphocytes were overexpressed in 
active SLE patients. Accordingly, we observed that IL-36α exerted substantial proinflammatory effect in 
SLE patients by inducing the production of IL-6 and CXCL8. Furthermore, the percentage of IL-36R+ B 
lymphocytes correlated negatively with the frequency of Breg lymphocytes, providing evidence that the 
pathophysiology of SLE may be linked to a complex immune relationship between IL-36 and Breg subsets. 
Therefore, these results can provide better understanding for the overexpression and proinflammatory 
role of IL-36α in patients with SLE.  
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